Sigma-Aldrich Enters South Korean Pharma Market

Photo courtesy of Bloomberg

Sigma-Aldrich Corp. has signed an agreement with Seoul, South Korea-based CrystalGenomics to develop pharmaceutical ingredients for next-generation non-steroidal anti-inflammatory drugs (NSAID), the company announced today.

The agreement, reached by Sigma-Aldrich’s custom manufacturing and services business unit, SAFC, will expand the company’s reach into the growing South Korean pharmaceutical market. With this agreement, CrystalGenomics will use SAFC’s Pharmorphix pre-formulation technology to analyze active pharmaceutical ingredients. Read more on St. Louis Business Journal.

Tags:, , ,

Leave a Reply

Have you heard?

Missouri Business Alert is participating in CoMoGives2019!

Find out how we plan to use your gift to enhance training and programming for our students

Learn more